2-(4-(苄氧基)亚苄基)丙二酸二乙酯 | 53361-40-3

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: 2-(4-(苄氧基)亚苄基)丙二酸二乙酯
• 英文名称: diethyl 2-(4-(benzyloxy)benzylidene)malonate
• 英文别名: Diethyl-(4-benzyloxyphenylmethylen)-malonat；diethyl 2-[(4-phenylmethoxyphenyl)methylidene]propanedioate
• CAS: 53361-40-3
• 化学式: C₂₁H₂₂O₅
• mdl: MFCD12547117
• 分子量: 354.403
• InChiKey: VWHQKXNYOOUFKX-UHFFFAOYSA-N

物化性质

• 沸点：
  222 °C(Press: 0.1 Torr)
• 密度：
  1.164±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.238
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-(4-(苄氧基)亚苄基)丙二酸二乙酯 在 sodium hydride 、 magnesium iodide 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 9.5h， 生成 diethyl 4-(4-(benzyloxy)phenyl)-1-tosylazetidine-2,2-dicarboxylate
  参考文献：
  名称：

  Ring Expansion of Donor–Acceptor Cyclopropane via Substituent Controlled Selective N-Transfer of Oxaziridine: Synthetic and Mechanistic Insights

  摘要：

  A distinctive N-substituent controlled electrophilic N-transfer of oxaziridines with donor-acceptor cyclopropanes in the presence of MgI2 is reported. Contrary to earlier reports, the oxaziridine having bulkier N-substituents can also give N-transferred product instead of the O-transferred one. Interestingly, the oxaziridines having alpha-H containing N-substituents lead to the pyrrolidine derivatives through [3 + 2] cycloaddition. A mechanistic reasoning for this divergent reactivity 18 depicted by density functional theory calculations and validated through energy decomposition analysis.

  DOI：

  10.1021/acs.orglett.6b02417
• 作为产物：
  描述：

  4-苄氧基苯甲醛 、 丙二酸二乙酯 在 哌啶 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 12.0h， 生成 2-(4-(苄氧基)亚苄基)丙二酸二乙酯
  参考文献：
  名称：

  来自丙二酸二乙酯或β-溴-α-羟基亚氨基羧酸乙酯的非天然α-氨基乙酯。

  摘要：

  我们在这里探索了基于古老的丙二酸二乙酯对α-氨基酯的接触范围，该方法涉及丙二酸二乙酯在醛上的Knoevenagel缩合反应，所得亚烷基丙二酸酯的还原，相应α-羟基亚氨基酯的制备及其最终还原。尽管遇到了一些意想不到的限制，但这种合成途径被证明是通用的。在进行肟化步骤之前，使用Suzuki-Miyaura偶联或环加成法对某些中间体进行了合成修饰，从而获得了更多的α-氨基酯。此外，探索了其他通往α-羟基亚氨基酯的途径，包括试图改善乙基β-溴-α-羟基亚氨基羧酸酯与各种烷基呋喃化合物之间的环加成反应。

  DOI：

  10.3762/bjoc.14.264

文献信息

• Piperidine derivatives having renin inhibiting activity
  申请人：Hoffmann-La Roche Inc.

  公开号：US06051712A1

  公开（公告）日：2000-04-18

  Novel piperidine derivatives, their manufacture and use as medicaments, are disclosed. The invention is concerned with the novel piperidine derivatives of general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, X, Z, m and n are as described herein.

  揭示了一种新的哌啶衍生物的制备和用途作为药物。该发明涉及一般式I的新的哌啶衍生物 ##STR1## 其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、Q、X、Z、m和n如本文所述。
• Methods of treating alzheimer's disease
  申请人：Nieman A. James

  公开号：US20060079533A1

  公开（公告）日：2006-04-13

  Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of 3,4-disubstituted piperidinyl compounds of formula (I) wherein the variables R 1 , R 2 , R 3 , R 4 , Q, W, X, Z, m, and n are defined herein.

  本发明公开了一种治疗阿尔茨海默病和其他疾病、抑制β-分泌酶酶和/或抑制哺乳动物中A beta肽沉积的方法，使用式(I)的3,4-二取代哌啶基化合物，其中变量R1、R2、R3、R4、Q、W、X、Z、m和n在此定义。
• Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: Virtual screening, synthesis, and biological evaluation
  作者：Guanghui Deng、Weihua Li、Jianhua Shen、Hualiang Jiang、Kaixian Chen、Hong Liu

  DOI：10.1016/j.bmcl.2008.09.027

  日期：2008.10

  The identification of a novel pyrazolidine-3,5-dione based scaffold hit compound as Farnesoid X receptor (FXR) partial or full agonist has been accomplished by means of virtual screening techniques. A series of pyrazolidine-3,5-dione derivatives (1a-u and 7) was designed, synthesized, and evaluated by a cell-based luciferase transactivation assay for their agonistic activities against FXR. Most of them showed agonistic potencies and 10 of them (1a, 1b, 1d-f, 1j, 1n, 1t, 5b, and 7) exhibited lower EC(50) values than the reference drug CDCA. Molecular modeling studies for the representative compounds 1a, 1d, 1f, 1j, 1n, 1u, 5b, and 7 were also presented. The novel structural scaffold has provided a new direction for finding potent and selective FXR partial and full agonists (referred to as 'selective bile acid receptor modulators', SBARMs). (c) 2008 Elsevier Ltd. All rights reserved.
• US6051712A
  申请人：——

  公开号：US6051712A

  公开（公告）日：2000-04-18
• US6150526A
  申请人：——

  公开号：US6150526A

  公开（公告）日：2000-11-21